Document:

EXHIBIT 10.4

 

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (the
“Agreement”) is made and entered into as of November 18, 2013, by and among Stratus Media Group, Inc., a Nevada
corporation (the “Company”), and those Persons listed on Appendix A (the “Holders”).

Recitals

A.                 
Pursuant to an Agreement and Plan
of Merger entered into among the Company, Canterbury Acquisition, LLC, a Delaware limited liability company, Hygeia Acquisition,
Inc., a Delaware corporation, Canterbury Laboratories, LLC, a Delaware limited liability company, Hygeia Therapeutics, Inc., a
Delaware corporation, and Yael Schwartz, Ph.D., (the “Merger Agreement”) concurrently herewith, the Company
is issuing to the Holders an aggregate of not more than 115,011,563 shares of the Common Stock of the Company (the “Shares”).

B.                 
In connection with that issuance,
the Company has agreed to grant to the Holders certain registration rights with respect to the Shares on the terms set forth herein.

C.                 
Capitalized terms used and not
otherwise defined herein shall have the meanings given such terms in the Merger Agreement.

Agreements

NOW, THEREFORE, in consideration of their
respective promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and the Holders hereby agree as follows:

1.                 
Definitions. As used in this Agreement, the following terms shall have the specified meanings:

“Affiliate” means,
with respect to any Person, any other Person that directly or indirectly controls or is controlled by or under common control with
such Person. For the purposes of this definition, “control,” when used with respect to any Person, means the possession,
direct or indirect, of the power to direct or cause the direction of the management and policies of such Person, whether through
the ownership of voting securities, by contract or otherwise, and the terms “affiliated,” “controlling”
and “controlled” have meanings correlative to the foregoing.

“Business Day” means
any day except Saturday, Sunday and any day which shall be a legal holiday or a day on which banking institutions in the State
of California are authorized or required by law or other government actions to close.

“Commission” means
the Securities and Exchange Commission.

“Common Stock” means
the Company’s $0.001 par value common stock.

“Exchange Act” means
the Securities Exchange Act of 1934, as amended.

    	1

    	 

    

“Holder” or “Holders”
means the holder or holders, as the case may be, from time-to-time of the Registrable Securities.

“Person” means an
individual or a corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or political subdivision thereof) or other entity of any kind.

“Proceeding” means
an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such
as a deposition), whether commenced or threatened.

“Prospectus” means
the prospectus included in a registration statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A under the
Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion
of the Registrable Securities covered by such registration statement, and all other amendments and supplements to the Prospectus,
including post-effective amendments, and all material incorporated by reference in such Prospectus.

“Registrable Securities”
means (i) the Shares, (ii) any shares issuable upon any stock split, stock dividend, recapitalization or similar event with respect
to the Shares and (iii) any other dividend or other distribution with respect to, conversion or exchange of, or in replacement
of, the Shares.

“Rule 144” means Rule
144 under the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted
by the Commission having substantially the same effect as such Rule.

“Rule 158” means Rule
158 under the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted
by the Commission having substantially the same effect as such Rule.

“Securities Act” means
the Securities Act of 1933, as amended.

“Shares” means the
shares of Common Stock issued pursuant to the Merger Agreement as set forth on Appendix A.

2.                 
Registration.

(a)               
Piggy-Back Registrations.

    	2

    	 

    

(i)                
If at any time (but without any obligation to do so) when there is not already an effective registration statement covering
the Registrable Securities, the Company shall decide to prepare and file with the Commission a registration statement relating
to an offering for its own account of any of its equity securities or the account of other holders of any of its equity securities,
other than on Form S-4 or Form S-8 (or their then equivalents relating to equity securities to be issued solely in connection with
the acquisition of an entity or business, or equity securities issuable in connection with stock option or other employee benefit
plans or a registration in which the only stock being registered is Common Stock issuable upon conversion of debt securities which
are also being registered, or any registration on any form which does not include substantially the same information as would be
required to be included in a registration statement covering the sale of the Registrable Securities), the Company shall send to
each Holder written notice of such decision, and, to the extent permitted under the provisions of Rule 145 under the Securities
Act, include in such registration all Registrable Securities with respect to which the Company has received written requests for
inclusion therein within fifteen (15) days after receipt of such notice, on the same terms and conditions as the securities otherwise
being sold in such registration, subject to the Company’s right to exclude a Holder as set forth below; provided, however,
that if at any time after giving written notice of its intention to register any securities and prior to the effective date of
the registration statement filed in connection with such registration, the Company shall determine for any reason not to register
or to delay registration of such securities, the Company may, at its election, give written notice of such determination to each
selling Holder and, thereupon, (i) in the case of a determination not to register, shall be relieved of its obligation to register
any Registrable Securities in connection with such registration (but not from its obligation to pay expenses in accordance with
Section 5 hereof) and (ii) in the case of a determination to delay registering, shall be permitted to delay registering any Registrable
Securities being registered pursuant to this Section 2(a) for the same period as the delay in registering such other securities.
The foregoing notwithstanding, the Company shall not be required to register any Registrable Securities pursuant to this Section
2(a) if (i) such Registrable Securities are eligible for sale pursuant to Rule 144 and (ii) upon presentation of the appropriate
legal opinion and other documentation typically required for the sale of restricted securities under Rule 144, the Company acts
promptly in allowing (or causing its stock transfer agent to allow) the sale of such Registrable Securities.

(ii)              
In the case of an underwritten public offering, if the managing underwriter(s) should reasonably object to the inclusion
of the Registrable Securities in such registration statement, then if the Company, after consultation with the managing underwriter(s),
should reasonably determine that the inclusion of the Registrable Securities would materially adversely affect the offering contemplated
in such registration statement, and based on such determination recommends inclusion in such registration statement of fewer or
none of the Registrable Securities of a Holder, then (A) if the Company after consultation with the underwriter(s) recommends the
inclusion of fewer Registrable Securities, the number of Registrable Securities of the Holders included in such registration statement
shall be reduced pro-rata among such Holders (based upon the number of Registrable Securities requested to be included in the registration),
or (B) if the Company after consultation with the underwriter(s) recommends the inclusion of none of the Registrable Securities,
none of the Registrable Securities of any Holder shall be included in such registration statement; provided, however, that if securities
are being offered for the account of other Persons as well as the Company who have greater priority than the Holders, then the
amount of the Registrable Securities otherwise to be included in the registration statement shall be reduced by the amount of the
securities having greater priority.

    	3

    	 

    

(b)              
“Market Stand-Off” Agreement. Each Holder hereby agrees that, if requested by the Company or the representative
of the underwriters of Registrable Securities of the Company, such Holder shall not sell, dispose of, transfer, make any short
sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as
a sale, any Registrable Securities of the Company held by such Holder (other than those included for sale in the registration or
acquired in the Company’s first firm commitment underwritten public offering of its Common Stock registered and declared
effective under the Securities Act or in the open market thereafter) for a period specified by the representative of the underwriters
of equity securities of the Company not to exceed 180 days (or such longer period as the underwriters or the Company shall request
in order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation) following
the effective date of a registration statement of the Company filed under the Securities Act; provided that the same lock-up is
agreed to by all directors and officers of the Company and shareholders individually owning more than 1% of the Company’s
outstanding Common Stock. Any discretionary waiver or termination of the restrictions of such agreements by the Company or representatives
of the underwriters shall apply to the Holders, pro rata, based on their percentage equity ownership in the Company.

(c)               
Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated
by it under this Section 2 prior to or following the effectiveness of such registration, whether or not any Holder has Registrable
Securities included in such registration.

3.                 
Registration Procedures. If and whenever the Company effects the registration of any Registrable Securities, the
Company shall:

(a)               
Initial Filing. Not less than five Business Days prior to the filing of the registration statement or any related
Prospectus or any amendment or supplement thereto (including any document that would be incorporated therein by reference), (i)
furnish to each selling Holder copies of all such documents proposed to be filed, which documents (other than those incorporated
by reference) will be subject to the review of each such selling Holder and (ii) at the request of a selling Holder, and subject
to the execution of a confidentiality agreement in form and substance reasonably satisfactory to the Company, cause the Company’s
officers, directors, counsel and independent certified public accountants to respond to such inquiries as shall be necessary, in
the reasonable opinion of counsel to such selling Holder, to conduct a reasonable investigation within the meaning of the Securities
Act.

(b)              
Related Matters. Notify each Holder of Registrable Securities to be sold and any counsel therefor as promptly as
possible (and, in the case of clause (i)(A) below, not less than five Business Days prior to such filing) (i)(A) when a Prospectus
or any Prospectus supplement or post-effective amendment to a registration statement is proposed to be filed, (B) when the Commission
notifies the Company whether there will be a “review” of such registration statement and whenever the Commission comments
in writing on such registration statement and (C) with respect to a registration statement or any post-effective amendment, when
the same has become effective, (ii) of any request by the Commission or any other federal or state governmental authority for amendments
or supplements to a registration statement or Prospectus or for additional information, (iii) of the issuance by the Commission
of any stop order suspending the effectiveness of a registration statement covering any or all of the Registrable Securities or
the initiation of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the
suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction,
or the initiation or threatening of any Proceeding for such purpose and (v) of the occurrence of any event that makes any statement
made in a registration statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue
in any material respect or that requires any revisions to a registration statement, Prospectus or other documents so that, in the
case of such registration statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading.

    	4

    	 

    

(c)               
Incorporation of Certain Matters. If requested by the Holders of a majority of the Registrable Securities for which
written requests have been received by the Company pursuant to Section 2(a) in connection with an offering, (i) promptly incorporate
in a Prospectus supplement or post-effective amendment to a registration statement such information as the Company reasonably agrees
should be included therein and (ii) make all required filings of such Prospectus supplement or such post-effective amendment as
soon as practicable after the Company has received notification of the matters to be incorporated therein.

(d)              
Copies. To the extent requested by any Holder, provide to each Holder and any counsel therefor, without charge, at
least one conformed copy of each registration statement and each amendment thereto (including financial statements and schedules,
documents incorporated or deemed to be incorporated therein by reference, and all exhibits), such documents to be provided promptly
after their filing with the Commission.

(e)               
Delivery. Promptly deliver to each Holder and any counsel therefor, without charge, as many copies of the Prospectus
or Prospectuses and each amendment or supplement thereto as they may reasonably request; and the Company hereby consents to the
use of each such Prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offer
and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto.

(f)               
Blue Sky Matters. (A) Prior to any public offering of the Registrable Securities, use commercially reasonable efforts
to register or qualify or cooperate with the selling Holders and any counsel therefor in connection with the registration or qualification
(or exemption from such registration or qualification) of such Registrable Securities for offer and sale under the securities laws
(the “Blue Sky laws”) of such jurisdictions within the United States as any Holder reasonably requests in writing
and (B) perform or do any and all other acts or things necessary or advisable to enable the disposition in such jurisdictions of
those Registrable Securities covered by a registration statement; provided, however, that the Company shall not be required to
qualify generally to do business in any jurisdiction where it is not then so qualified or to take any action that would subject
it to general service of process in any such jurisdiction where it is not then so subject or subject the Company to any material
tax in any such jurisdiction where it is not then so subject.

(g)              
Preparation of Certificates. Cooperate with each Holder to facilitate the timely preparation and delivery of certificates
representing Registrable Securities to be sold pursuant to a registration statement, which certificates shall be free of all restrictive
legends, and cause such certificates to be in such denominations and registered in such names as each Holder may request at least
two Business Days prior to any sale of Registrable Securities.

    	5

    	 

    

(h)              
Misrepresentation. Upon the occurrence of any event contemplated by Section 3(b)(v), as promptly as possible, prepare
a supplement or amendment, including a post-effective amendment, to the registration statement or a supplement to the related Prospectus
or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as
thereafter delivered, neither such registration statement nor such Prospectus will contain an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading.

(i)                
Listing and Quotation. Use its commercially reasonable efforts to cause all Registrable Securities offered by a registration
statement to be quoted on any securities exchange, quotation system or other market on which similar securities issued by the Company
are then listed or quoted.

(j)                
Rule 158. Comply in all material respects with all applicable rules and regulations of the Commission and make generally
available to its security holders an earnings statement satisfying the provisions of Section 11(a) of the Securities Act and Rule
158 not later than 45 days after the end of any twelve-month period (or 90 days after the end of any twelve-month period if such
period is a fiscal year) commencing on the first day of the first fiscal quarter of the Company after the effective date of the
registration statement.

4.                 
Additional Matters.

(a)               
Holder Information. In connection with a registration statement, each selling Holder shall be required to furnish
to the Company information regarding such Holder and the distribution of such Registrable Securities as is required by law to be
disclosed in the registration statement, and the Company may exclude from such registration the Registrable Securities of any such
Holder who fails to furnish such information within a reasonable time prior to the filing of such registration statement or any
supplemented Prospectus and/or amended registration statement.

(b)              
Reference to Holder. If a registration statement refers to any Holder by name as the holder of any securities of
the Company, then such Holder shall have the right to require the deletion of the reference to such Holder in any amendment or
supplement to the registration statement that is filed subsequent to the time that such reference ceases to be required by the
Securities Act.

(c)               
Holder Covenants. Each Holder covenants and agrees that (i) it will not sell any Registrable Securities under a registration
statement until it has received copies of the Prospectus as then amended or supplemented as contemplated in Section 3(g) and notice
from the Company that such registration statement and any post-effective amendments thereto have become effective as contemplated
by Section 3(c) and (ii) it and its officers, directors and Affiliates, if any, will comply with the prospectus delivery requirements
of the Securities Act as applicable to them in connection with the sale of Registrable Securities pursuant to such registration
statement.

    	6

    	 

    

(d)              
Discontinuance. Each Holder agrees by its acquisition of Registrable Securities that, upon receipt of a notice from
the Company of the occurrence of any event of the kind described in clauses (ii) through (v) of Section 3(b) or suspension of the
use of the registration statement pursuant to Section 2(c) hereof, such Holder will immediately discontinue disposition of such
Registrable Securities under the registration statement until such Holder’s receipt of the copies of the supplemented Prospectus
and/or amended registration statement contemplated by Section 3(h), or until it is advised in writing by the Company that the use
of the applicable Prospectus may be resumed, and, in either case, has received copies of any additional or supplemental filings
that are incorporated or deemed to be incorporated by reference in such Prospectus or registration statement.

5.                 
Registration Expenses. All fees and expenses incident to the performance of or compliance with this Agreement by
the Company shall be borne by the Company, whether or not a registration statement is filed or becomes effective and whether or
not any Registrable Securities are sold pursuant to a registration statement; provided, however, that all underwriting discounts
and selling commissions applicable to the Registrable Securities shall be borne by the Holders selling such Registrable Securities,
in proportion to the number of Registrable Securities sold by each such Holder. Such fees and expenses shall include, without limitation,
(i) all registration and filing fees (including, without limitation, fees and expenses (A) with respect to filings required to
be made by or with each securities exchange, quotation system or other market on which Registrable Securities are required hereby
to be listed or quoted, (B) with respect to filings required to be made with the Commission and (C) in compliance with applicable
Blue Sky laws (including, without limitation, reasonable fees and disbursements of counsel for each Holder in connection with Blue
Sky law qualifications of the Registrable Securities and any determination of the eligibility of the Registrable Securities for
investment under the laws of such jurisdictions as the Holders of a majority of Registrable Securities may designate)), (ii) printing
expenses (including, without limitation, expenses of printing certificates for the Registrable Securities and of printing Prospectuses,
if the printing of Prospectuses is requested by the Holders of a majority of the Registrable Securities included in the registration
statement), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company and fees and
disbursements, not to exceed $10,000, of a single counsel for the Holders, (v) Securities Act liability insurance, if the Company
so desires such insurance and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation
of the transactions contemplated by this Agreement, including, without limitation, the Company’s independent public accountants
(including any costs associated with the delivery by independent public accountants of a comfort letter or comfort letters). In
addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the
transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees
performing legal or accounting duties), the expense of any annual audit, and the fees and expenses incurred in connection with
the listing or quoting of the Registrable Securities on any securities exchange, quotation system or other market on which Registrable
Securities are required to be listed or quoted. If the Holders are required to pay any registration expenses not payable by the
Company pursuant hereto, such expenses shall be borne by the holders of securities (including Registrable Securities) requesting
such registration in proportion to the number of shares for which registration was requested.

    	7

    	 

    

6.                 
Indemnification.

(a)               
Indemnification by the Company. To the extent permitted by law, the Company shall, notwithstanding any termination
of this Agreement, defend, indemnify and hold harmless each Holder, each officer, director, manager, owner, agent and employee
of each Holder, each Person who controls any Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act) and each officer, director, manager, owner, agent and employee of each such controlling Person, to the fullest extent
permitted by applicable law, from and against any and all losses, claims, damages, liabilities, reasonable costs (including, without
limitation, costs of investigation, preparation and reasonable attorneys’ fees actually incurred) and expenses (collectively,
“Losses”), as incurred, arising out of or relating to any untrue or alleged untrue statement of a material fact
contained in a registration statement or any Prospectus or any amendment or supplement thereto, or arising out of or relating to
any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in
the case of any Prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading,
except to the extent, but only to the extent, that (i) such untrue statements or omissions are based solely upon information regarding
such Holder which was furnished in writing to the Company by such Holder expressly for use therein, (ii) such information relates
to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly
approved in writing by such Holder for use in the registration statement or such Prospectus or in any amendment or supplement thereto
or (iii) the use by such Holder of an outdated or defective prospectus (without any Company provided supplement correcting such
outdated or defective prospectus) after the Company has notified such Holder in writing that such prospectus is suspended from
use, outdated or defective. The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding
of which the Company is aware in connection with the transactions contemplated by this Agreement. Such indemnity shall remain in
full force and effect regardless of any investigation made by or on behalf of an Indemnified Party and shall survive the transfer
of Registrable Securities by a Holder.

(b)              
Indemnification by Holders. To the extent permitted by law, each Holder shall, severally and not jointly, defend,
indemnify and hold harmless the Company, the Company’s directors, officers, agents and employees, each Person who controls
the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers,
agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses,
as incurred, arising solely out of or based solely upon any untrue statement of a material fact contained in a registration statement,
any Prospectus or any amendment or supplement thereto, or arising solely out of or based solely upon any omission of a material
fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto,
in the light of the circumstances under which they were made) not misleading, to the extent, but only to the extent, that (i) such
untrue statement or omission is contained in or omitted from any information so furnished in writing by such Holder to the Company
specifically for inclusion in such registration statement or such Prospectus or an amendment or supplement thereto, (ii) such information
relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly
approved in writing by such Holder expressly for use in such registration statement or such Prospectus or any amendment or supplement
thereto or (iii) the use by such Holder of an outdated or defective prospectus (without any Company provided supplement correcting
such outdated or defective prospectus) after the Company has notified such Holder in writing that such prospectus is suspended
from use, outdated or defective. Notwithstanding anything to the contrary contained herein, a Holder shall be liable under this
Section 6(b) for only that amount which does not exceed the net proceeds to such Holder as a result of the sale of Registrable
Securities pursuant to such registration statement.

    	8

    	 

    

(c)               
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled
to indemnity hereunder (an “Indemnified Party”), such Indemnified Party promptly shall notify the Person from
whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall assume the
defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees
and expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice
shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the
extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or
further review) that such failure shall have proximately and materially adversely prejudiced the Indemnifying Party. An Indemnified
Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (i) the Indemnifying Party
has agreed in writing to pay such fees and expenses, (ii) the Indemnifying Party shall have failed promptly to assume the defense
of such Proceeding following receipt of notice and to employ counsel reasonably satisfactory to such Indemnified Party in any such
Proceeding or (iii) the named parties to any such Proceeding (including any impleaded parties) include both the Indemnified Party
and the Indemnifying Party, and the Indemnified Party shall have been advised by counsel that a conflict of interest is likely
to exist if the same counsel were to represent both the Indemnified Party and the Indemnifying Party (in which case, if the Indemnified
Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party,
the Indemnifying Party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the Indemnifying
Party). If the Indemnifying Party is not entitled to, or elects not to, assume the defense of a claim, it will not be obligated
to pay the fees and expenses of more than one counsel with respect to such claim. The Indemnifying Party shall not be liable for
any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld. No
Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding
in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified
Party from all liability on claims that are the subject matter of such Proceeding. All fees and expenses of the Indemnified Party
(including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding
in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within 30 Business Days of
written notice thereof to the Indemnifying Party (regardless of whether it is ultimately determined that the Indemnified Party
is not entitled to indemnification hereunder; provided, that the Indemnifying Party may require the Indemnified Party to undertake
to reimburse all such fees and expenses to the extent it is finally judicially determined that the Indemnified Party is not entitled
to indemnification hereunder).

    	9

    	 

    

(d)              
Contribution. If a claim for indemnification under Section 6(a) or 6(b) is unavailable to an Indemnified Party because
of a failure or refusal of a governmental authority to enforce such indemnification in accordance with its terms (by reason of
public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to
the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect
the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that
resulted in such Losses, as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party
and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue
or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or
relates to information supplied by, such Indemnifying, Party or Indemnified Party, and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable as a
result of any Losses shall be deemed to include, subject to the limitations set forth in Section 6(c), any reasonable attorneys’
or other reasonable fees or expenses incurred in connection with any Proceeding to the extent there would have been indemnification
for such fees or expenses if the indemnification provided in this Section was available in accordance with its terms. Notwithstanding
anything to the contrary contained herein, a Holder shall be liable or required to contribute under this Section 6(d) for only
such amount as does not exceed the net proceeds to such Holder as a result of the sale of Registrable Securities pursuant to the
registration statement. The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section
6(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable
considerations referred to in this paragraph. No Person guilty of fraudulent misrepresentation (within the meaning provided in
the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.
The indemnity and contribution agreements contained in this Section are in addition to any liability that an Indemnifying Party
may have to an Indemnified Party.

7.                 
Rule 144. For so long as any Holder owns any Shares, the Company agrees to timely file (or obtain extensions in respect
thereof and file within the applicable extension period) all reports required to be filed by the Company pursuant to Section 13
or 15(d) of the Exchange Act. In addition, as long as any Holder owns any Shares, if the Company is not required to file reports
pursuant to Section 13 or 15(d) of the Exchange Act, it will prepare and furnish to each Holder and make publicly available in
a timely fashion the information specified in Rule 144. Subject to Section 8, the Company further agrees that it will take
such further action as any Holder may reasonably request to the extent required from time-to-time to enable each Holder to sell
Shares without registration under the Securities Act within the limitation of the exemption provided by Rule 144 including promptly
causing its counsel, at the Company’s cost, to issue an opinion permitting resale subject to Holder providing necessary documentation.

    	10

    	 

    

8.                 
Lock-Up Shares. In consideration of the Company agreeing to enter into this Agreement each Holder hereby agrees that
until the expiration of twelve (12) months following the date of this Agreement (the “Lock-Up Period”), such
Holder will not make, offer to make, agree to make, or suffer any Disposition (as defined below) of the Shares beneficially owned
by the Holders or any interest therein. For the purposes of this Agreement, “Disposition” shall mean any sale,
exchange, assignment, gift, pledge, mortgage, hypothecation, transfer or other disposition or encumbrance of all or any part of
the rights and incidents of ownership of the Shares, including the right to vote, and the right to possession of the Shares as
collateral for indebtedness, whether such transfer is outright or conditional, or for or without consideration. Notwithstanding
anything in this Agreement to the contrary, (x) Shares may be transferred upon the death of any Holder to the estate, representatives,
and heirs of the deceased Holder and (y) the Holders shall be permitted to transfer the Shares for estate planning purposes provided
that, in either case of (x) or (y), any transferee takes subject to this Agreement. The Holder hereby agrees that, during the Lock-Up
Period, the Holder will not (i) grant any proxies or powers of attorney that would permit any such proxy or attorney-in-fact
to take any action inconsistent herewith, (ii) deposit such Holder’s Shares into a voting trust or enter into a voting agreement
with respect to the Shares; or (iii) take any action that would make any representation or warranty of any Holder untrue or incorrect
or would result in a breach by the Holder of such Holder’s obligations under this Agreement. The Holder further agrees not
to enter into any agreement or understanding with any other person or entity, the effect of which would be inconsistent with or
violative of any provision contained in this Agreement.

9.                 
Miscellaneous.

(a)               
Remedies. In the event of a breach by the Company or any Holder of any of their obligations under this Agreement,
each non-breaching party, in addition to being entitled to exercise all rights granted by law or under this Agreement, including
recovery of damages, will be entitled to specific performance of its rights under this Agreement. The Company and each Holder agree
that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the
provisions of this Agreement and hereby further agree that, in the event of any action for specific performance in respect of such
breach, it shall waive the defense that a remedy at law would be adequate. The Company and the Holders also acknowledge and agree
that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance
with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction
or injunctions to prevent or cure breaches of the provisions of this Agreement and to enforce specifically the terms and provisions
hereof, this being in addition to any other remedy to which any of them may be entitled by law or equity.

(b)              
Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, shall not be
amended, modified or supplemented, and waivers or consents to departures from the provisions hereof shall not be given, unless
the same shall be in writing and signed by the Company and the applicable Holder. Notwithstanding the foregoing, a waiver or consent
to depart from the provisions hereof with respect to a matter that relates generally to the rights of the Holders may be given
by Holders of at least a majority of the Registrable Securities to which such waiver or consent relates; provided, however, that
the provisions of this sentence may not be amended, waived, modified, or supplemented except in accordance with the provisions
of the immediately preceding sentence. Notwithstanding the foregoing, Appendix A may be amended by the Company to reflect transfers
of Registrable Securities and changes in contact information without the consent of any party hereto.

    	11

    	 

    

(c)               
Notices. Any and all communications required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective as provided in the Merger Agreement. The addresses for such communications shall be as set forth
on Appendix A hereto or such other address or addresses as a party may most recently have designated in writing to the other
party hereto.

(d)              
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and permitted assigns. The Holders may not assign this Agreement or any of its rights or obligations hereunder without
the prior written consent of the Company.

(e)               
Assignment of Registration Rights. Subject to Section 8, the rights of each Holder hereunder, including the
right to have the Company register for resale Registrable Securities in accordance with the terms of this Agreement, shall be automatically
assignable by each Holder to any transferee of such Holder of all or a portion of the Registrable Securities if: (i) the Holder
agrees in writing with the transferee to assign such rights and a copy of such agreement is furnished to the Company, (ii) the
Company is furnished with written notice of (A) the name and address of such transferee or assignee and (B) the securities
with respect to which such registration rights are being transferred or assigned, (iii) following such transfer or assignment the
further disposition of such securities by the transferee or assignees is restricted under the Securities Act and applicable state
securities laws, (iv) the transferee agrees in writing with the Company to be bound by all of the provisions of this Agreement
and (v) such transfer shall have been made in accordance with applicable federal and state securities laws. The rights to assignment
shall apply to each Holder and to their subsequent successors and assigns.

(f)               
Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed shall
be deemed to be an original and, all of which taken together shall constitute one and the same agreement. In the event that any
signature is delivered by facsimile transmission, such signature shall create a valid binding obligation of the party executing
(or on whose behalf such signature is executed) such document with the same force and effect as if such facsimile signature were
the original thereof.

(g)              
Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Nevada
without regard to the principles of conflict of laws. The parties hereto agree that a final, non-appealable judgment in any suit
or proceeding with respect to this Agreement shall be conclusive and may be enforced in other jurisdictions by suit on such judgment
or in any other lawful manner.

(h)              
Cumulative Remedies. No provision of this Agreement providing for any specific remedy to a party shall be construed
to limit such party to the specific remedy described, and that any other remedy that would otherwise be available to such party
at law or in equity shall also be available. The parties also intend that the rights and remedies hereunder be cumulative, so that
exercise of any one or more of such rights or remedies shall not preclude the later or concurrent exercise of any other rights
or remedies.

    	12

    	 

    

(i)                
Severability. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity
or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or
the validity or enforceability of any provision of this Agreement in any other jurisdiction.

(j)                
Headings; Interpretation. The headings of this Agreement are for convenience of reference and shall not form a part
of, or affect the interpretation of, this Agreement. As used herein, (i) the neuter gender includes the masculine or feminine and
the singular number includes the plural, and vice versa, as the context may require and (ii) unless the context clearly requires
otherwise, the words “herein,” “hereunder” and “hereby,” shall refer to this entire Agreement
and not only to the Section or paragraph in which such word appears. If any date specified herein falls upon a Saturday, Sunday
or public or legal holidays, the date shall be construed to mean the next Business Day following such Saturday, Sunday or public
or legal holiday. Each party intends that this Agreement be deemed and construed to have been jointly prepared by the parties.
As a result, the parties agree that any uncertainty or ambiguity existing herein shall not be interpreted against either of them.

(k)              
Attorney’s Fees. If any party to this Agreement shall bring any action for relief against the other arising
out of or in connection with this Agreement, in addition to all other remedies to which the prevailing party may be entitled, the
losing party shall be required to pay to the prevailing party a reasonable sum for attorney’s fees and costs incurred in
bringing or defending such action and/or enforcing any judgment granted therein, all of which shall be deemed to have accrued upon
the commencement of such action and shall be paid whether or not such action is prosecuted to judgment. Any judgment or order entered
in such action shall contain a specific provision providing for the recovery of attorney’s fees and costs incurred in enforcing
such judgment. For the purposes of this Section, attorney’s fees shall include, without limitation, reasonable fees incurred
with respect to the following: (i) post-judgment motions, (ii) contempt proceedings, (iii) garnishment, levy and debtor and third
party debtor and third party examinations, (iv) discovery and (v) bankruptcy litigation.

(l)                
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

[Remainder of page intentionally left blank]

 

    	13

    	 

    

 

IN WITNESS WHEREOF, the Holders and
the Company have caused this Agreement to be duly executed by their respective authorized persons on the date first written above.

	 	 
	 	
	 	 
	 	STRATUS MEDIA GROUP, INC.
	 	 
	 	 
	 	By:_____________________________
	 	      Name:_________________________
	 	      Title:__________________________
	 	 
	 	 
	 	 
	 	
	 	 
	 	 
	 	 
	 	________________________________
	 	
	 	 

 

    	14

    	 

    

Appendix A

HOLDERS AND REGISTRABLE SECURITIES

	Name of Holder	Contact Information	Registrable Securities
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	15EXHIBIT 10.5

 

EXCLUSIVE LICENSE AGREEMENT

THIS AGREEMENT (the “Agreement”)
by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly
of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and Hygeia Therapeutics, Inc.,
a corporation organized and existing under the laws of the State of Delaware, and with principal offices located in Holden, MA
(“LICENSEE”) is effective as of October 26th, 2007 (“EFFECTIVE DATE”).

ARTICLE
1. BACKGROUND

1.1.           
In the course of research conducted under YALE auspices, Dr. Richard B. Hochberg, in the Department of Obstetrics, Gynecology
and Reproductive Sciences at YALE (the “INVENTOR”), has produced an invention entitled “15a-Substituted Estradiol
Carboxylic Acid Esters as Locally Active Estrogens (OCR #1400)” (the “INVENTION”).

1.2.           
INVENTOR has assigned to YALE of all INVENTOR’s right, title and interest in and to the INVENTION and any resulting
patents.

1.3.           
YALE wishes to have the INVENTION and any resulting patents commercialized to benefit the public good.

1.4.           
LICENSEE has represented to YALE to induce YALE to enter into this Agreement that it shall act diligently to develop and
commercialize the LICENSED PRODUCTS for public use throughout the LICENSED TERRITORY (as defined below).

1.5.           
YALE is willing to grant a license to LICENSEE, subject to the terms and conditions of this Agreement.

1.6.           
In consideration of these statements and mutual promises, YALE and LICENSEE agree to the terms of this Agreement.

ARTICLE 2. DEFINITIONS

The following terms used in this Agreement
shall be defined as set forth below:

2.1.           
“AFFILIATE” shall mean any entity or person that directly or indirectly controls, is controlled by or is under
common control with LICENSEE. For purposes of this definition, “control” means possession of the power to direct the
management of such entity or person, whether through ownership of more than fifty percent (50%) of voting securities, by contract
or otherwise.

2.2.           
“CONFIDENTIAL INFORMATION” shall mean all information disclosed by one party to the other during the negotiation
of or under this Agreement in any manner, whether orally, visually or in tangible form, that relates to LICENSED PATENTS, LICENSED
INFORMATION or the Agreement itself, unless such information is subject to an exception described in Article 82, CONFIDENTIAL INFORMATION
that is disclosed in tangible form shall be marked “Confidential” at the time of disclosure and CONFIDENTIAL INFORMATION
that is disclosed orally or visually shall be identified as confidential at the time of disclosure and subsequently reduced to
writing, marked confidential and delivered to the other party within thirty (30) days of such disclosure, CONFIDENTIAL INFORMATION
shall include, without limitation, the following, whether or not patentable: materials, know-how and data (whether technical or
non-technical), trade secrets, inventions, methods and processes. Notwithstanding any other provisions of this Article 2.2, CONFIDENTIAL
INFORMATION of LICENSEE that is subject to Article 8 of this Agreement is limited to information that LICENSEE supplies pursuant
to LICENSEE’s obligations under Articles 7 and 9 of this Agreement, unless otherwise mutually agreed to in writing by the
parties.

    	1

    	 

    

2.3.           
“CHANGE OF CONTROL” shall mean (a) any consolidation, merger, combination, reorganization or other transaction
in which LICENSEE is not the surviving entity, (b) the shares of stock of LICENSEE constituting in excess of fifty (50%) of the
voting power of LICENSEE are exchanged for or changed into other stock or securities, cash, and/or any other property, or (c) a
sale or other disposition of all or substantially all of the assets of LICENSEE.

2.4.           
“EARNED ROYALTY” is defined in Article 6.1.

2.5.           
“EFFECTIVE DATE” is defined in the introductory paragraph of this Agreement.

2.6.           
“FIELD” shall mean all uses, including without limitation, the diagnosis, prevention and treatment of any and
all diseases or conditions in mammals.

2.7.           
“FIRST SALE” shall mean the first sale to a third party of any LICENSED PRODUCT or LICENSED METHOD in any country.

2.8.           
“IND” shall mean an investigational new drug application filed with the United States Food and Drug Administration
prior to beginning clinical trials in humans in the United States or any comparable application filed with regulatory authorities
in or for a country or group of countries other than the United States.

2.9.           
“INVENTION” and “INVENTOR” are defined in Article 1.1.

2.10.       
“INSOLVENT” shall mean that LICENSEE (i) has ceased to pay its debts in the ordinary course of business, (ii)
has current assets that are insufficient to pay its current obligations, (iii) is insolvent as defined by the United States Federal
Bankruptcy Law, as amended from time to time, or (iv) has commenced bankruptcy, reorganization, receivership or insolvency proceedings,
or any other proceeding under any Federal, state or other law for the relief of debtors.

2.11.       
“LICENSE” refers to the license granted under Article 3.1.

2.12.       
“LICENSED INFORMATION” shall mean all inventions, concepts, processes, information, data, know-how and the like
that are owned by YALE and in YALE’s possession as of the EFFECTIVE DATE, not claimed in a patent or patent application,
and necessary for the use, manufacture or sale of LICENSED PRODUCTS or the practice of LICENSED METHODS.

    	2

    	 

    

2.13.       
“LICENSED METHODS” shall mean any method, procedure, service or process the practice of which, in the absence
of a license from YALE, would infringe a VALID CLAIM of a LICENSED PATENT or which uses a LICENSED PRODUCT.

2.14.       
“LICENSED PATENTS” shall mean the United States or foreign patent application(s) and patents(s) listed in Appendix
A and owned by YALE during the TERM of this Agreement, together with any continuations, divisionals, and continuations-in-part,
to the extent the claims of any such patent or patent application are directed to subject matter specifically described in the
patent applications listed on Appendix A; any reissues, re-examinations, or extensions thereof, or substitutes therefor; and the
relevant international equivalents of any of the foregoing. Appendix A is incorporated into this Agreement.

2.15.       
“LICENSED PRODUCTS” shall mean any product (including any apparatus or kit) or component part thereof, the manufacture,
use or sale of which, in the absence of a license from YALE, would infringe a VALID CLAIM of a LICENSED PATENT.

2.16.       
“LICENSED TERRITORY” shall mean worldwide.

2.17.       
“NDA” shall mean a new drug application filed with the United States Food and Drug Administration to obtain
marketing approval for a LICENSED PRODUCT in the United States or any comparable application filed with a regulatory authority
in or for a country or group of countries other than the United States.

2.18.       
“NET SALES” shall mean:

(a)               
gross invoice price from the sale, lease or other transfer or disposition of the LICENSED PRODUCTS or LICENSED METHODS,
or from services performed using LICENSED PRODUCTS or LICENSED METHODS, by LICENSEE, SUBLICENSEES or AFFILIATES to third parties,
except as set forth in Article 2.17(b), less the following deductions, provided they actually pertain to the disposition of the
LICENSED PRODUCTS or LICENSED METHODS and appear separately on an invoice:

(i)              
all discounts, credits, rebates, chargebacks and allowances;

(ii)            
transportation and insurance; and

(iii)          
duties, taxes and other governmental charges levied on the sale, transportation or delivery of LICENSED PRODUCTS or practice
of the LICENSED METHODS, but not including income taxes.

No deductions shall be made for any other costs or expenses,
including but not limited to commissions to independents, agents or those on LICENSEE’s, SUBLICENSEE’s or an AFFILIATE’s
payroll or for the cost of collection.

(b)              
“NET SALES” shall not include the gross invoice price for LICENSED PRODUCTS or LICENSED METHODS sold to, or
services performed using LICENSED PRODUCTS or LICENSED METHODS for, any AFFILIATE unless such AFFILIATE is an end-user of any LICENSED
PRODUCT or LICENSED METHOD, in which case such consideration shall be included in NET SALES at the average selling price charged
to a third party during the same quarter.

    	3

    	 

    

2.19.       
“PHASE I” shall mean a clinical trial of a LICENSED PRODUCT or LICENSED METHOD in human subjects where the purpose
of the clinical trial is to assess the safety, tolerability, pharmacokinetics, biomarker response, and/or pharmacodynamics of a
LICENSED PRODUCT or LICENSED METHOD. PHASE I shall also mean a first trial of each new formulation or preparation of a LICENSED
PRODUCT or LICENSED METHOD for any reason. In the event that a PHASE I trial becomes a proof of concept trial in order to assess
clinical efficacy a ‘‘PHASE I/II” trial, the trial shall be considered a PHASE II trial.

2.20.       
“PHASE II” shall mean a human clinical trial that is intended to initially evaluate the effectiveness of a drug
for a particular indication or indications in patients with the disease or indication under study or that would otherwise satisfy
requirements of 21 CFR 312.21(b) in the United States of America or the equivalent of such regulation in another country or jurisdiction.

2.21.       
“PHASE III” shall mean a human clinical trial that is designed to establish that a drug is safe and efficacious
for its intended use, and to define warnings, precautions and adverse reactions that are associated with the drug in the dosage
range to be prescribed, and designed to support regulatory approval of such drug or label expansion of such drug.

2.22.       
“REASONABLE COMMERCIAL EFFORTS” shall mean documented efforts that are consistent with those utilized by companies
of similar size and type that have successfully developed products and services similar (meaning products that are similar with
respect to the stage of development, patent coverage, market potential and safety and efficacy profile) to LICENSED PRODUCTS and
LICENSED METHODS. In determining REASONABLE COMMERCIAL EFFORTS with respect to a particular LICENSED PRODUCT or LICENSED METHOD,
LICENSEE may not reduce such efforts due to the competitive, regulatory or other impact of any other product or method that it
owns, licenses or is developing or commercializing.

2.23.       
“SUBLICENSE INCOME” shall mean consideration in any form received by LICENSEE or an AFFILIATE in consideration
with the grant to any third party or parties of a sublicense or other right, license, privilege or immunity to make, have made,
use, sell, have sold, distribute, import or export LICENSED PRODUCTS or to practice LICENSED METHODS, but excluding consideration
included within EARNED ROYALTIES. For avoidance of doubt, a sublicense shall not include the right of a purchaser of a LICENSED
PRODUCT to re-sell or distribute, on a wholesale retail or other basis, the LICENSED PRODUCT as part of the established supply
chain for pharmaceutical products. SUBLICENSE INCOME shall include without limitation any license signing fee, license maintenance
fee, unearned portion of any minimum royalty payment received by LICENSEE, distribution or joint marketing fee, research and development
funding in excess of LICENSEE’s cost of performing such research and development, and any consideration received for an equity
interest in, extension of credit to or other investment in LICENSEE to the extent such consideration exceeds the fair market value
of the equity or other interest received as determined by agreement of the parties or by an independent appraiser mutually agreeable
to the parties.

    	4

    	 

    

2.24.       
“SUBLICENSEE” shall mean any third party sublicensed by LICENSEE to make, have made, use, sell, have sold, import
or export any LICENSED PRODUCT or to practice any LICENSED METHOD.

2.25.       
“TERM” is defined in Article 3.4.

2.26.       
“VALID CLAIM” shall mean a pending, issued or unexpired claim of a LICENSED PATENT so long as such claim shall
not have been irrevocably abandoned or declared to be invalid in an unappealable decision of a court or other authority or competent
jurisdiction through no fault of cause of LICENSEE.

ARTICLE 3. LICENSE
GRANT AND TERM

3.1.           
Subject to all the terms and conditions of this Agreement, YALE hereby grants to LICENSEE an exclusive license, under the
LICENSED PATENTS, with the right to grant sublicenses, to make, have made, use, sell, have sold, import and export LICENSED PRODUCTS,
and to practice any LICENSED METHOD, within the FIELD in the LICENSED TERRITORY (the “LICENSE”), and a non-exclusive
license under the LICENSED INFORMATION, with the right to grant sublicenses, to use LICENSED INFORMATION solely for activities
related to any LICENSED PRODUCT or LICENSED METHOD.

3.2.           
To the extent that any invention included within the LICENSED PATENTS has been funded in whole or in part by the United
States government, the United States government retains certain rights in such invention as set forth in 35 U.S.C. §200-212
and all regulations promulgated thereunder, as amended, and any successor statutes and regulations (the “Federal Patent Policy”).
As a condition of the license granted hereby, LICENSEE acknowledges and shall comply with all aspects of the Federal Patent Policy
applicable to the LICENSED PATENTS, including the obligation that LICENSED PRODUCTS used or sold in the United States be manufactured
substantially in the United States. Nothing contained in this Agreement obligates or shall obligate YALE to take any action that
would conflict in any respect with its past, current or future obligations to the United States Government under the Federal Patent
Policy with respect to the LICENSED PATENTS.

3.3.           
The LICENSE is expressly made subject to YALE’s reservation of the right to make, use and practice the LICENSED PATENTS,
LICENSED METHODS and LICENSED INFORMATION for research, clinical, teaching or other non-commercial purposes, and to give academic
research institutions access to the LICENSED PATENTS, LICENSED METHODS and LICENSED INFORMATION for research, clinical, or teaching
purposes and not for purposes of commercial development, use, manufacture or distribution. Nothing in this Agreement shall be construed
to grant by implication, estoppel or otherwise any licenses tinder patents of YALE other than the LICENSED PATENTS.

3.4.           
Unless terminated earlier as provided in Article 13, the term of the LICENSE shall commence on the EFFECTIVE DATE and shall
automatically expire on the date on which the last of the claims of the patents described in the LICENSED PATENTS expires, lapses
or is declared to be invalid by a non-appealable decision of a court of competent jurisdiction through no fault or cause of LICENSEE
(the “TERM”).

    	5

    	 

    

3.5.           
Upon expiration of this Agreement, the LICENSE granted in Artide 3,1 shall automatically convert to a paid-up, non-exclusive
license.

3.6.           
Upon conversion to a non-exclusive license under Article 3.5, the LICENSEE’s right to grant any sublicense terminates
and each existing sublicense shall convert to a paid-up, non-exclusive license in the applicable country.

3.7.           
Within 30 days of the EFFECTIVE DATE, YALE shall disclose the LICENSED INFORMATION to LICENSEE, which LICENSEE shall be
entitled to use as provided in this Article 3.

3.8.           
Except as expressly provided in this Agreement, under no circumstances will LICENSEE, as a result of this Agreement, obtain
any interest in or any other right to any technology, know-how, patents, patent applications, materials or other intellectual or
proprietary property of YALE.

ARTICLE 4. SUBLICENSES

4.1.           
LICENSEE shall have the full right to sublicense the rights granted to it under this Agreement, through one or more tiers,
subject to the requirements of this Article 4.

4.2.           
Any sublicense granted by LICENSEE shall include substantially the same definitions and provisions on Due Diligence, Confidentiality
and Publicity, Reporting Requirements, Indemnification, Insurance and Warranties, Patent Notices and Use of YALE’s Name,
as are agreed to in this Agreement, and such other provisions as are needed to enable LICENSEE to comply with this Agreement. LICENSEE
will provide YALE with a copy of each Sublicense Agreement (and all amendments thereof) promptly after execution. LICENSEE shall
remain responsible for the performance of all SUBLICENSEES under any such sublicense as if such performance were carried out by
LICENSEE itself, including, without limitation, the payment of any royalties or other payments provided for hereunder, regardless
of whether the terms of any sublicense provide for such amounts to be paid by the SUBLICENSEE directly to YALE. A breach of this
provision shall constitute a material breach that is subject to Article 13.1(b).

4.3.           
LICENSEE shall pay royalties to YALE on NET SALES of SUBLICENSEES based on the same royalty rate as apply to NET SALES by
LICENSEE and its AFFILIATES, regardless of the royalty rates payable by SUBLICENSEES to LICENSEE under a sublicense agreement.
In addition, LICENSEE shall pay to YALE Fifteen Per Cent (15%) of any SUBLICENSE INCOME.

4.4.           
LICENSEE agrees that it has sole responsibility to promptly:

(a)               
provide YALE with a copy of any amendments to sublicenses granted by LICENSEE under this Agreement and to notify YALE of
termination of any sublicense; and

(b)              
summarize and deliver copies of all reports provided to LICENSEE by SUBLICENSEES.

    	6

    	 

    

ARTICLE 5. LICENSE
ISSUE ROYALTY; LICENSE MAINTENANCE

ROYALTY; MILESTONE ROYALTIES; EQUITY

5.1.           
Within ten (10) business days after the EFFECTIVE DATE, LICENSEE shall convey to YALE, Thirty Two (32) shares (the “Shares”)
of LICENSEE’ s common stock representing five percent (5%) of LICENSEE’s total outstanding shares. The Shares shall
be fully-paid and are non-assessable upon issuance to YALE and shall be subject to a shareholder agreement and restrictions on
transfer. LICENSEE represents to YALE that LICENSEE, has not issued any securities other than common stock, nor rights to receive
any securities in the LICENSEE, to any third party as of the EFFECTIVE DATE.

5.2.           
Within ninety (90) days after the EFFECTIVE DATE, LICENSEE shall pay to YALE Sixteen Thousand Seven Hundred Eighty One dollars
and Ten cents (US $16,781,10) as reimbursement in full for all past patent expenses incurred by YALE.

5.3.           
During the TERM of this Agreement, LICENSEE agrees to pay to YALE an annual license maintenance royalty (“LMR”)
commencing on the first anniversary of the EFFECTIVE DATE and every anniversary thereafter until LICENSEE starts to pay Minimum
Royalty Payments under Article 6.3 according to the following schedule:

	Anniversary of EFFECTIVE DATE	LMR
	1st	$1,000.00
	2nd	$2,500.00
	3rd	$5,000.00
	4th	$10,000.00
	5th and each anniversary thereafter until MRP commencement	$25,000.00

 

5.4.           
LICENSEE shall pay the following milestone royalties to YALE for each LICENSED PRODUCT developed by LICENSEE. For avoidance
of doubt, for purposes of this Section 5.4, LICENSED PRODUCTS that contain the same active ingredient(s), but that are different
in other respects, for example LICENSED PRODUCTS that have different approved indications, formulations or dosages, shall be considered
to be a single “LICENSED PRODUCT” and only one set of the following milestones shall be payable in connection with
the development and regulatory approval of such LICENSED PRODUCTS no matter how many times a particular milestone is achieved.
For further clarification, if two LICENSED PRODUCTS having different active ingredients achieve the same milestones, then each
of those milestones shall be payable in respect of each such LICENSED PRODUCT.

(a)               
a non-refundable milestone royalty of Fifty Thousand Dollars ($50,000.00) when LICENSEE receives IND approval for such LICENSED
PRODUCT.

(b)              
a non-refundable milestone royalty of Fifty Thousand Dollars ($50,000,00) when LICENSEE initiates PHASE II for such LICENSED
PRODUCT. The PHASE II study shall be deemed to have been initiated when the first patient has been treated with the investigational
agent under the first PHASE II clinical protocol.

    	7

    	 

    

(c)               
a non-refundable milestone royalty of Three Hundred Thousand Dollars ($300,000.00) when LICENSEE initiates PHASE III for
such LICENSED PRODUCT, The PHASE III study shall be deemed to have been initiated when the first patient has been treated with
the investigational agent under the first PHASE III clinical protocol.

(d)              
a non-refundable milestone royalty of Two Hundred Thousand Dollars ($200,000) upon completion of patient enrollment in the
first PHASE III study.

(e)               
a non-refundable milestone royalty of One Million Two Hundred Thousand Dollars ($1,200,000.00) when LICENSEE receives NDA
approval for such LICENSED PRODUCT.

5.5.           
Neither the license issue royalty set forth in Article 5.1 nor the patent reimbursement payments of Article 5.2 nor the
LMR of Article 5.3 nor the milestone royalties set forth in Article 5.4 shall be credited against EARNED ROYALTIES payable under
Article 6.

ARTICLE 6. EARNED
ROYALTIES MINIMUM ROYALTY PAYMENTS

6.1.           
During the TERM of this Agreement, as partial consideration for the LICENSE, LICENSEE shall pay to YALE an earned royalty
on worldwide annual NET SALES of LICENSED PRODUCTS or LICENSED METHODS by LICENSEE or its SUBLICENSEES or AFFILIATES in each calendar
year (“EARNED ROYALTIES”) according to the following schedule:

	Annual NET SALES	EARNED ROYALTY
	0 to $100,000,000	2%
	$100,000,001 to $200,000,000	2.5%
	Over $200,000,000	3%

 

6.2.           
LICENSEE shall pay all EARNED ROYALTIES accruing to YALE within thirty (30) days from the end of each calendar quarter (March
31, June 30, September 30 and December 31), beginning in the first calendar quarter in which NET SALES occur.

6.3.           
During the term of this Agreement, LICENSEE agrees to pay YALE total annual Minimum Royalty Payments (“MRP”),
commencing on the first anniversary of the date of FIRST SALE of the first LICENSED PRODUCT according to the following schedule:

	1st anniversary	$100,000.00
	2nd anniversary	$100,000.00
	3rd anniversary	$200,000. 00
	4th anniversary	$300,000,00
	5th anniversary	
        $400,000.00 and each anniversary thereafter

 

LICENSEE shall continue to pay the MRP until the end of the
TERM, YALE shall fully credit each MRP made against any EARNED ROYALTIES payable by LICENSEE in the same year.

    	8

    	 

    

6.4.           
All EARNED ROYALTIES and other payments due under this Agreement shall be paid to YALE in United States Dollars. In the
event that conversion from foreign currency is required in calculating a payment under this Agreement, the exchange rate used shall
be the Interbank rate quoted by Citibank at the end of the last business day of the quarter in which the royalty was earned. If
overdue, the royalties and any other payments due under this Agreement shall bear interest until payment at a per annum rate two
percent (2%) above the prime rate in effect at Citibank on the due date and YALE shall be entitled to recover reasonable attorneys’
fees and costs related to the administration or enforcement of this Agreement, including collection of royalties or other payments,
following such failure to pay. The payment of such interest shall not foreclose YALE from exercising any other right it may have
as a consequence of the failure of LICENSEE to make any payment when due.

6.5.           
In the event that a patent included within LICENSED PATENTS expires or lapses, or if all of its claims are declared invalid
by a non-appealable decision of a court of competent jurisdiction, the obligation to pay EARNED ROYALTIES and MRP for LICENSED
PRODUCTS and LICENSED METHODS covered by the invalidated patent claim(s) shall be reduced by Fifty Percent (50%) if the LICENSED
PRODUCT or LICENSED METHOD is not covered by any remaining LICENSED PATENTS or claims thereunder, but the LICENSED PRODUCT or LICENSED
METHOD incorporates or relies upon LICENSED INFORMATION for its manufacture or use. This Agreement shall remain in effect as to
any other LICENSED PRODUCTS and LICENSED METHODS covered by any remaining LICENSED PATENT or remaining claims under the LICENSED
PATENTS.

ARTICLE 7. DUE
DILIGENCE

7.1.           
LICENSEE has designed a plan for developing and commercializing the LICENSED PATENTS that includes a description of research
and development, testing, government approval, manufacturing, marketing and sale or lease of LICENSED PRODUCTS and/or LICENSED
METHODS (“PLAN”), A copy of the PLAN is attached to this Agreement as Appendix C and incorporated herein by reference,

7.2.           
LICENSEE shall use REASONABLE COMMERCIAL EFFORTS, within one hundred eighty (180) days after the EFFECTIVE DATE of this
Agreement, to begin to implement the PLAN at its sole expense and thereafter to diligently commercialize and develop markets for
the LICENSED PRODUCTS and LICENSED METHODS.

7.3.           
LICENSEE shall provide YALE with an updated and revised copy of the PLAN on each anniversary date of the EFFECTIVE DATE,

7.4.           
Within thirty (30) days of each anniversary of the EFFECTIVE DATE of this Agreement, LICENSEE shall provide a written report
to YALE, indicating LICENSEE’s progress and problems to date in performance under the PLAN, commercialization of LICENSED
PRODUCTS and LICENSED METHODS, and a forecast and schedule of major events required to market the LICENSED PRODUCTS. Within thirty
(30) days following any assignment by LICENSEE pursuant to Section 17.6, the assignee shall provide YALE with an updated and revised
copy of the PLAN.

    	9

    	 

    

7.5.           
LICENSEE shall immediately notify YALE if at any time LICENSEE (a) abandons or suspends its research, development or marketing
of the LICENSED PRODUCTS and or LICENSED METHODS, or its intent to research, develop and market such products or methods, or (b)
fails to comply with its due diligence obligations under this Article for a period exceeding ninety (90) days.

7.6.           
LICENSEE agrees that YALE shall be entitled to terminate this Agreement pursuant to Article 13.1(b) upon the occurrence
of any of the following:

(a)               
LICENSEE shall fail to implement the PLAN in accordance with Article 7.4 or otherwise fails to fulfill any of its obligations
under Article 7.5, or this Article 7.6; or

(b)              
LICENSEE gives notice pursuant to Article 7.5 (which shall be deemed a material breach not capable of being cured); or

(c)               
LICENSEE has failed to initiate proof of concept studies in an established preclinical model (e.g., a primate model) within
two (2) years of the EFFECTIVE DATE.

(d)              
LICENSEE has failed to have raised equity capital of no less than $1,000,000.00 within two (2) years of the EFFECTIVE DATE.

(e)               
LICENSEE has failed to have filed an IND for a LICENSED PRODUCT or LICENSED METHOD within four (4) years of the EFFECTIVE
DATE.

(f)               
LICENSEE has failed, in any calendar year following the filing of an IND, to perform at least one of the following with
respect to LICENSED PRODUCT:

(i)              
expend one million dollars ($1,000,000.00) for development of LICENSED PRODUCT;

(ii)            
manufacture LICENSED PRODUCT for clinical trial under an approved IND;

(iii)          
actively conduct a PHASE I clinical trial with respect to LICENSED PRODUCT;

(iv)          
actively conduct a PHASE II clinical trial with respect to LICENSED PRODUCT;

(v)            
actively conduct a PHASE III clinical trial with respect to LICENSED PRODUCT;

(vi)          
prepare documents for NDA filing with respect to LICENSED PRODUCT;

(vii)        
make an NDA filing for LICENSED PRODUCT;

    	10

    	 

    

(viii)      
after NDA filing, pursue NDA approval for LICENSED PRODUCT;

(ix)          
receive an NDA approval for LICENSED PRODUCT; or

(x)            
launch or sell LICENSED PRODUCT in the United States or another major market (i.e., Canada, France, Germany, Italy, Japan
or the U.K.).

ARTICLE 8. CONFIDENTIALITY
AND PUBLICITY

8.1.           
Subject to the parties’ rights and obligations pursuant to this Agreement, YALE and LICENSEE agree that during the
term of this Agreement and for five (5) years thereafter, each of them:

(a)               
will keep confidential and will cause their AFFILIATES and, in the case of LICENSEE, its SUBLICENSEES, to keep confidential,
CONFIDENTIAL INFORMATION disclosed to it by the other party, by taking whatever action the party receiving the CONFIDENTIAL INFORMATION
would take to preserve the confidentiality of its own CONFIDENTIAL INFORMATION, which in no event shall be less than reasonable
care; and

(b)              
will only disclose that part of the other’s CONFIDENTIAL INFORMATION to its officers, employees or agents that is
necessary for those officers, employees or agents who need to know to carry out its responsibilities under this Agreement; and

(c)               
will not use the other party’s CONFIDENTIAL INFORMATION other than as expressly set forth in this Agreement or disclose
the other’s CONFIDENTIAL INFORMATION to any third parties under any circumstance without advance written permission from
the other party unless a confidentiality agreement is first executed between LICENSEE and such third party with terms and conditions
that are similar and consistent with those of this Agreement; and

(d)              
will, within sixty (60) days of termination of this Agreement, return all the CONFIDENTIAL INFORMATION disclosed to it by
the other party pursuant to this Agreement except for one copy which may be retained by the recipient for monitoring compliance
with this Article 8.

8.2.           
The obligations of confidentiality described above shall not pertain to that part of the CONFIDENTIAL INFORMATION that:

(a)               
was known to the recipient prior to the disclosure by the disclosing party; or

(b)              
is at the time of disclosure or has become thereafter publicly known through no fault or omission attributable to the recipient;
or

(c)               
is rightfully given to the recipient from sources independent of the disclosing party; or

    	11

    	 

    

(d)              
is independently developed by the receiving party without use of or reference to the CONFIDENTIAL INFORMATION of the other
party as evidenced by written records; or

(e)               
is required to be disclosed by law in the opinion of recipient’s attorney, but only after the disclosing party is
given prompt written notice and an opportunity to seek a protective order.

8.3.           
Except as required by law, neither party may disclose the financial terms of this Agreement without the prior written consent
of the other party.

ARTICLE 9. REPORTS,
RECORDS AND INSPECTIONS

9.1.           
LICENSEE shall, within thirty (30) days after the calendar year in which NET SALES first occur, and within thirty (30) days
after each calendar quarter (March 31, June 30, September 30 and December 31) thereafter, provide YALE with a written report detailing
the NET SALES and uses, if any, made by LICENSEE, its SUBLICENSEES and AFFILIATES of LICENSED PRODUCTS and LICENSED METHODS during
the preceding calendar quarter and calculating the payments due pursuant to Article 6. NET SALES of LICENSED PRODUCTS or LICENSED
METHODS shall be deemed to have occurred on the date of invoice for such LICENSED PRODUCTS or LICENSED METHODS. Each such report
shall be signed by an officer of LICENSEE (or the officer’s designee), and must include:

(a)               
the number of LICENSED PRODUCTS manufactured, sold, leased or otherwise transferred or disposed of, and the amount of LICENSED
METHODS sold, by LICENSEE, SUBLICENSEES and AFFILIATES;

(b)              
a calculation of NET SALES for the applicable reporting period in each country, including the gross invoice prices charged
for the LICENSED PRODUCTS and LICENSED METHODS and any permitted deductions made pursuant to Article 2.18;

(c)               
a calculation of total royalties or other payment due, including any exchange rates used for conversion; and

(d)              
names and addresses of all SUBLICENSEES and the type and amount of any SUBLICENSE INCOME received from each SUBLICENSEE.

9.2.           
LICENSEE and its SUBLICENSEES shall keep and maintain complete and accurate records and books containing an accurate accounting
of all data in sufficient detail to enable verification of EARNED ROYALTIES and other payments under this Agreement. LICENSEE shall
preserve such books and records for three (3) years after the calendar year to which they pertain. Such books and records shall
be open to inspection by YALE or an independent certified public accountant selected by YALE, at YALE’s expense, during normal
business hours upon ten ( 10) days’ prior written notice, for the purpose of verifying the accuracy of the reports and computations
rendered by LICENSEE, In the event LICENSEE underpaid the amounts due to YALE with respect to the audited period by more than five
percent (5%), LICENSEE shall pay the reasonable cost of such examination, together with the deficiency not previously paid, within
thirty (30) days of receiving notice thereof from YALE.

    	12

    	 

    

9.3.           
On or before the ninetieth (901h) day following the close of LICENSEE’s fiscal year, LICENSEE shall provide YALE with
LICENSEE’s certified financial statements for the preceding fiscal year including, at a minimum, a balance sheet and an income
statement. All information contained in such certified financial statements are hereby deemed to be CONFIDENTIAL INFORMATION of
LICENSEE for all purposes under this Agreement.

ARTICLE 10. PATENT
PROTECTION

10.1.       
LICENSEE shall reimburse YALE for all reasonable and customary costs of filing, prosecution and maintenance of all United
States patent applications contained in the LICENSED PATENTS accrued as of the EFFECTIVE DATE or during the TERM of this Agreement.
Any and all such United States patent applications, and resulting issued patents, shall remain the property of YALE.

10.2.       
LICENSEE shall reimburse YALE for all reasonable and customary costs, accrued as of the EFFECTIVE DATE or during the TERM
of this Agreement, of filing, prosecution and maintenance of all foreign patent applications, and patents contained in the LICENSED
PATENTS in the countries outside the United States in the LICENSED TERRITORY selected by YALE and agreed to by LICENSEE. All such
applications or patents shall remain the property of YALE.

10.3.       
If LICENSEE does not agree to pay the expenses of filing, prosecuting or maintaining a patent application or patent in any
country outside the United States, or fails to pay the expenses of filing, prosecuting or maintaining a patent application or patent
in the United States, then LICENSEE’s rights under this Agreement with respect to such patent or patent application shall
terminate automatically with respect to that country.

10.4.       
The costs mentioned in Articles 10.1 and 102 shall include, but are not limited to, any past, present and future taxes,
annuities, working fees, maintenance fees, renewal and extension charges. Payment of such costs shall be made, at YALE’s
option, either directly to patent counsel or by reimbursement to YALE. In either case, LICENSEE shall make payment directly to
the appropriate party within thirty (30) days of receiving its invoice. If LICENSEE fails to make payment to YALE or patent counsel,
as appropriate, within the thirty day period, LICENSEE shall be charged a five percent (5%) surcharge on the invoiced amount per
month or fraction thereof or such higher amount as may be charged by patent counsel. Failure of LICENSEE to pay the surcharge shall
be grounds for termination by YALE under Article 13.1 (b).

10.5.       
All patent applications under the LICENSED PATENTS shall be prepared, prosecuted, filed and maintained by independent patent
counsel chosen by YALE and reasonably acceptable to LICENSEE. Said independent patent counsel shall be ultimately responsible to
YALE. YALE shall instruct patent counsel to keep both YALE and LICENSEE fully informed of the progress of all patent applications
and patents, and to give both YALE and LICENSEE reasonable opportunity to comment on the type and scope of useful claims and the
nature of supporting disclosures. YALE will not abandon any patent application for which LICENSEE is bearing expenses without LICENSEE’s
consent. Yale shall have no liability to LICENSEE for damages, whether direct, indirect or incidental, consequential or otherwise,
allegedly arising from its good faith decisions, actions and omissions in connection with such prosecution.

    	13

    	 

    

10.6.       
LICENSEE shall mark, and shall require SUBLICENSEES to mark, all LICENSED PRODUCTS with the numbers of all patents included
in LICENSED PATENTS that cover the LICENSED PRODUCTS. Without limiting the foregoing, all LICENSED PRODUCTS shall be marked in
such a manner as to conform with the patent marking notices required by the law of any country where such LICENSED PRODUCTS are
made, sold, used or shipped, including, but not limited to, the applicable patent laws of that country.

ARTICLE 11. INFRINGEMENT
AND LITIGATION

11.1.       
Each party shall promptly notify the other in writing in the event that it obtains knowledge of infringing activity by third
parties, or is sued or threatened with an inf•ingement suit, in any country in the LICENSED TERRITORY as a result of activities
that concern the LICENSED PATENTS and shall supply the other party with documentation of the infringing activities that it possesses.

11.2.       
During the TERM of this Agreement:

(a)               
LICENSEE shall have the first right and obligation to use REASONABLE COMMERCIAL EFFORTS to defend the LECENSED PA’1ENTS
against infringement or interference in the FIELD and in the LICENSED TERRITORY by third parties. This right and obligation includes
bringing any legal action for infringement and defending any counter claim of invalidity or action of a third party for declaratory
judgment for non-infringement or non-interference. If, in the reasonable opinion of both LICENSEE’s and YALE’s respective
counsel, YALE is required to be a named party to any such suit for standing purposes, LICENSEE may join YALE as a party; provided,
however, that (i) YALE shall not be the first named party in any such action, (ii) the pleadings and any public statements
about the action shall state that the action is being pursued by LICENSEE and that LICENSEE has joined YALE as a party; and (iii)
LICENSEE shall keep YALE reasonably apprised of all developments in any such action. LICENSEE may settle such suits solely in its
own name and solely at its own expense and through counsel of its own selection; provided, however, that no settlement
shall be entered without YALE’s prior written consent. LICENSEE shall bear the expense of such legal actions. Except for
providing reasonable assistance, at the request and expense of LICENSEE, YALE shall have no obligation regarding the legal actions
described in Article 11.2 unless required to participate by law. However, YALE shall have the right to participate in any such
action through its own counsel and at its own expense. Any recovery shall first be applied to LICENSEE’s out of pocket expenses,
including legal fees, and second shall be applied to YALE’s out of pocket expenses, including legal fees. YALE shall recover
amounts awarded for lost sales at the royalty rate for those sales as described in Article 6.1 and 25% of any additional compensation
that may be awarded.

(b)              
In the event LICENSEE fails to exercise REASONABLE COMMERCIAL EFFORTS to initiate and pursue the actions described in Article
11.2(a) within sixty (60) days of (a) notification of infringement from YALE or (b) the date LICENSEE otherwise first becomes aware
of an infringement, whichever is earlier, YALE shall have the right to initiate such legal action at its own expense and YALE may
use the name of LICENSEE as party plaintiff to uphold the LICENSED PATENTS. In such case, LICENSEE shall provide reasonable assistance
to YALE if requested to do so. YALE may settle such actions solely through its own counsel. Any recovery shall be retained by YALE.
Under such circumstances, YALE may terminate the LICENSE in the country where such legal action is taken.

    	14

    	 

    

11.3.       
In the event LICENSEE is permanently enjoined from exercising its LICENSE under this Agreement pursuant to an infringement
action brought by a third party, or if both LICENSEE and YALE elect not to undertake the defense or settlement of a suit alleging
infringement for a period of six (6) months from notice of such suit, then either party shall have the right to terminate this
Agreement with respect to the LICENSED PATENTS in the country where the suit was filed with respect to the licensed patent following
thirty (30) days’ written notice to the other party in accordance with the terms of Article 15.

ARTICLE 12. USE
OF YALE’S NAME

LICENSEE shall not use the name “Yale”
or “Yale University,” nor any variation or adaptation thereof, nor any trademark, tradename or other designation owned
by YALE, nor the names of any of its trustees, officers, faculty, students, employees or agents, for any purpose without the prior
written consent of YALE in each instance, except that LICENSEE may state that it has licensed from YALE one or more of the patents
and/or applications comprising the LICENSED PATENTS.

ARTICLE
13. TERMINATION

13.1.       
YALE shall have the right to terminate this Agreement upon written notice to LICENSEE in the event LICENSEE:

(a)               
fails to make any payment whatsoever due and payable pursuant to this Agreement unless LICENSEE shall make all such payments
(and all interest due on such payments under Article 6.4) within the thirty (30) day period after receipt of written notice from
YALE; or

(b)              
commits a material breach of any other material provision of this Agreement which is not cured (if capable of being cured)
within the sixty (60) day period after receipt of written notice thereof from YALE, or upon receipt of such notice if such breach
is not capable of being cured; or

(c)               
fails to obtain or maintain adequate insurance as described in Article 14, whereupon YALE may terminate this Agreement immediately
upon written notice to LICENSEE.

13.2.       
This Agreement shall terminate automatically without any notice to LICENSEE in the event LICENSEE shall cease to carry on
its business or becomes INSOLVENT, or a petition in bankruptcy is filed against LICENSEE and is consented to, acquiesced in or
remains undismissed for sixty (60) days, or LICENSEE makes a general assignment for the benefit of creditors, or a receiver is
appointed for LICENSEE.

    	15

    	 

    

13.3.       
LICENSEE shall have the right to terminate this Agreement upon written notice to YALE:

(a)               
at any time on ninety (90) days notice to YALE, and upon payment of all amounts due YALE throughout the effective date of
termination; or

(b)              
in the event YALE commits a material breach of any of the material provisions of this Agreement and such breach is not cured
(if capable of being cured) within the sixty (60) day period after receipt of written notice thereof from LICENSEE, or upon receipt
of such notice if such breach is not capable of being cured.

13.4.       
Upon termination of this Agreement for any reason, all rights and licenses granted to LICENSEE under the terms of this Agreement
are terminated and YALE, in its sole discretion, may terminate any sublicense granted by LICENSEE. Upon such termination, LICENSEE
shall cease to manufacture LICENSED PRODUCTS, cease to use LICENSED INFORMATION and cease to practice LICENSED METHODS, unless
and until such manufacture, use or practice would no longer constitute an infringement of YALE’s intellectual property rights.
Within sixty (60) days of the effective date of termination LICENSEE shall return to YALE:

(a)               
all CONFIDENTIAL INFORMATION disclosed by YALE;

(b)              
the last report required under Article 7 or 9; and

(c)               
all payments incurred up to the effective date of termination.

Upon the occurrence of an uncured material breach by YALE
of any material provision of this AGREEMENT, each of LICENSEE’S payment obligations hereunder shall automatically be reduced
by fifty percent (50%) as and when each such payment becomes due and payable hereunder.

13.5.       
Termination of this Agreement shall not affect any rights or obligations accrued prior to the effective date of such termination
and specifically LICENSEE’s obligation to pay all royalties and other payments specified by Article 5 and 6. The following
provisions shall survive any termination: Articles 2 and 8, the preservation and inspection obligations of Article 9, Article 12,
this Article 13.5, Article 13.8, Article 14, Article 15, Article 16.1, and Article 17. The parties agree that claims giving rise
to indemnification may arise after the TERM or termination of the LICENSE granted herein.

13.6.       
The rights provided in this Article 13 shall be in addition and without prejudice to any other rights which the parties
may have with respect to any default or breach of the provisions of this Agreement.

13.7.       
Waiver by either party of one or more defaults or breaches shall not deprive such party of the right to terminate because
of any subsequent default or breach.

    	16

    	 

    

13.8.       
Upon termination of this AGREEMENT by YALE under Section 13.1 or by LICENSEE because LICENSEE has decided to abandon efforts
to develop and commercialize the LICENSED PRODUCTS, LICENSEE shall permit YALE and its future licensees to utilize, reference and
otherwise have the benefit of all regulatory approvals of, or clinical trials or other studies conducted on, and all filings made
with regulatory agencies with respect to, the LICENSED PRODUCTS or LICENSED METHODS subject to the terms and conditions of 14.2.
In addition, at YALE’s request, LICENSEE shall deliver to YALE all records required by regulatory authorities to be maintained
with respect to the sale, storage, handling, shipping and use of the LICENSED PRODUCTS or LICENSED METHODS, all reimbursement approval
files, all documents, data and information related to clinical trials and other studies of LICENSED PRODUCTS or LICENSED METHODS,
any other data, techniques, know-how and other information developed or generated that relate to the LICENSED PATENTS, LICENSED
PRODUCTS or LICENSED METHODS, and all copies and facsimiles of such materials, documents, information and files. YALE agrees that,
subject to the provisions of Article 8, LICENSEE may retain one copy thereof to the extent LICENSEE is required by law to maintain
such copy.

ARTICLE 14. INDEMNIFICATION;
INSURANCE; NO WARRANTIES

14.1.       
LICENSEE shall defend, indemnify and hold harmless YALE, its trustees, directors, officers, employees, and agents and their
respective successors, heirs and assigns against any and all liabilities, claims, demands, damages, judgments, losses and expenses
of any nature, including without limitation legal expenses and attorneys’ fees, arising out of any theory of liability (including
without limitation tort, warranty, or strict liability) or the death, personal injury, or illness of any person or out of damage
to any property related in any way to the exercise and/or practice by LICENSEE, its AFFILIATES, SUBLICENSEES or any other transferees
(other than YALE or its licensees or transferees as provided for in Section 13.8) of the rights granted under this Agreement, or
resulting from the production, manufacture, sale, use, lease, or other disposition or consumption or advertisement of the LICENSED
PRODUCTS or LICENSED METHODS by LICENSEE, its AFFILIATES, SUBLICENSEES or any other transferees (other than YALE or its licensees
or transferees as provided for in Section 13.8); or arising in connection with any statement, representation or warranty of LICENSEE,
its AFFILIATES, SUBLICENSEES or any other transferees (other than YALE or its licensees or transferees as provided for in Section
13.8) with respect to the LICENSED PRODUCTS or LICENSED METHODS.

14.2.       
If YALE exercises its right under Section 13.8, then, as a condition to YALE’s right to grant any licenses of its
rights thereunder, Yale shall secure from any future licensees agreement to defend, indemnify and hold harmless LICENSEE, its directors,
officers, employees, and agents and their respective successors, heirs and assigns against any and all liabilities, claims, demands,
damages, judgments, losses and expenses of any nature, including without limitation legal expenses and attorneys’ fees, arising
out of any theory of liability (including without limitation tort, warranty, or strict liability) or the death, personal injury,
or illness of any person or out of damage to any property related in any way to the exercise and/or practice by YALE or its licensees
or transferees of any rights granted to them as provided for in Section 13.8, including without limitation. the production, manufacture,
sale, use, lease, or other disposition or consumption or advertisement of products pursuant to the exercise of such rights.

    	17

    	 

    

14.3.       
A claim to which indemnification applies under Section 14.1 or Section 14.2 shall be referred to herein as an “Indemnification
Claim”. If any person or entity (collectively, the “Indemnitee”) intends to claim indemnification under this
Article 14, the Indemnitee shall notify the other Party (the “Indemnitor”) in writing promptly upon becoming aware
of any claim that may be an Indemnification Claim (it being understood and agreed, however, that the failure by an Indemnitee to
give such notice shall not relieve the Indemnitor of its indemnification obligation under this Agreement except and only to the
extent that the Indemnitor is actually prejudiced as a result of such failure to give notice). The indemnitor shall have the right
to assume and control the defense of the Indemnification Claim at its own expense with counsel selected by the Indemnitor and reasonably
acceptable to the Indemnitee, provided, however, that an Indemnitee shall have the right to retain its own counsel,
with the fees and expenses to be paid by the Indemnitee, if representation of such Indemnitee by the counsel retained by the Indemnitor
would be inappropriate due to actual or potential differing interests between such Indemnitee and any other party represented by
such counsel in such proceedings. If the Indemnitor does not assume the defense of the Indemnification Claim as aforesaid, the
Indemnitee may defend the Indemnification Claim but shall have no obligation to do so. The Indemnitee shall not settle or compromise
the Indemnification Claim without the prior written consent of the Indemnitor, and the Indemnitor shall not settle or compromise
the Indemnification Claim in any manner which would have an adverse effect on the Indemnitee’s interests, without the prior
written consent of the Indemnitee, which consent, in each case, shall not be unreasonably withheld or delayed. The Indemnitee shall
reasonably cooperate with the Indemnitor at the Indemnitor’s expense and shall make available to the Indemnitor all pertinent
information under the control of the Indemnitee.

14.4.       
LICENSEE shall purchase and maintain in effect and shall require its SUBLICENSEES to purchase and maintain in effect a policy
of commercial, general liability insurance to protect YALE with respect to events described in Article 14.1. Such insurance shall:

(a)               
list “YALE, its trustees, directors, officers, employees and agents” as additional insureds under the policy;

(b)              
provide that such policy is primary and not excess or contributory with regard to other insurance YALE may have;

(c)               
be endorsed to include product liability coverage in amounts no less than $2 Million Dollars per incident and $5 Million
Dollars annual aggregate; and

(d)              
be endorsed to include contractual liability coverage for LICENSEE’s indemnification under Article 14.1; and

(e)               
by virtue of the minimum amount of insurance coverage required under Article 14.4(c), not be construed to create a limit
of LICENSEE’s liability with respect to its indemnification under Article 14.1.

14.5.       
By signing this Agreement, LICENSEE certifies that the requirements of Article 14.4 will be met on or before the earlier
of (a) the date of FIRST SALE of any LICENSED PRODUCT or LICENSED METHOD or (b) the date any LICENSED PRODUCT, or LICENSED METHOD
is tested or used on humans, and will continue to be met thereafter. Upon YALE’s request, LICENSEE shall furnish a Certificate
of Insurance and a copy of the current Insurance Policy to YALE. LICENSEE shall give thirty (30) days’ written notice to
YALE prior to any cancellation of or material change to the policy.

    	18

    	 

    

14.6.       
(a)YALE MAKES NO REPRESENTATIONS OR WARRANTIES THAT ANY CLAIMS OF THE LICENSED PATENTS, ISSUED OR PENDING, ARE VALID,
OR THAT THE MANUFACTURE, USE, SALE OR OTHER DISPOSAL OF THE LICENSED PRODUCTS, OR PRACTICE OF THE LICENSED METHODS, OR USE OF THE
LICENSED INFORMATION DOES NOT OR WILL NOT INFRINGE ANY PATENT OR OTHER RIGHTS NOT VESTED IN YALE,

(b)YALE MAKES NO, AND EXPRESSLY DISCLAIMS
ALL WARRANTIES WHATSOEVER WITH RESPECT TO THE LICENSED PATENTS, LICENSED INFORMATION, LICENSED PRODUCTS AND LICENSED METHODS, EITHER
EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. LICENSEE
SHALL, MAKE NO STATEMENTS, REPRESENTATION OR WARRANTIES WHATSOEVER TO ANY THIRD PARTIES WHICH ARE INCONSISTENT WITH SUCH DISCLAIMER
BY YALE. IN NO EVENT SHALL YALE, OR ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES, BE LIABLE FOR SPECIAL, INCIDENTAL,
CONSEQUENTIAL OR INDIRECT DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF
WHETHER YALE SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING. EXCLUDING
AMOUNTS THAT MAY BECOME PAYABLE BY YALE’S FUTURE LICENSEES UNDER ARTICLE 14.2, IN NO OTHER EVENT SHALL YALE, OR ITS TRUSTEES,
DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES, BE LIABLE FOR DAMAGES IN EXCESS OF AMOUNTS YALE HAS RECEIVED FROM LICENSEE UNDER
THIS LICENSE.

ARTICLE 15. NOTICES,
PAYMENTS

15.1.       
Any payment, notice or other communication required by this Agreement (a) shall be in writing, (b) may be delivered personally
or sent by reputable overnight courier with written verification of receipt or by registered or certified first class United States
Mail, postage prepaid, return receipt requested, (c) shall be sent to the following addresses or to such other address as such
party shall designate by written notice to the other party, and (d) shall be effective upon receipt:

	
        FOR YALE:

        Managing Director

        YALE UNIVERSITY

        Office of Cooperative Research

        433 Temple Street

        New Haven, CT 06511
	
        FOR LICENSEE:

        Yael Schwartz

        Hygeia Therapeutics, Inc.

        8 Canterbury Lane

        Holden, MA 01520

 

 

    	19

    	 

    

 

ARTICLE 16. LAWS,
FORUM AND REGULATIONS

16.1.       
Any matter arising out of or related to this Agreement shall be governed by and in accordance with the substantive laws
of the State of Connecticut, without regard to its conflicts of law principles, except where the federal laws of the United States
are applicable and have precedence. Any dispute arising out of or related to this Agreement shall be brought in a court of competent
jurisdiction in the State of Connecticut.

16.2.       
LICENSEE shall comply, and shall cause its AFFILIATES and SUBLICENSEES to comply, with all foreign and United States federal,
state, and local laws, regulations, rules and orders applicable to the testing, production, transportation, packaging, labeling,
export, sale and use of the LICENSED PRODUCTS and practice of the LICENSED METHODS. In particular, LICENSEE shall be responsible
for assuring compliance with all United States export laws and regulations applicable to this LICENSE and LICENSEE’s activities
under this Agreement.

ARTICLE 17. MISCELLANEOUS

17.1.       
This Agreement shall be binding upon and inure to the benefit of the parties and their respective legal representatives,
successors and permitted assigns.

17.2.       
This Agreement constitutes the entire agreement of the parties relating to the LICENSED PATENTS, LICENSED PRODUCTS, LICENSED
METHODS and LICENSED INFORMATION, and all prior representations, agreements and understandings, written or oral, are merged into
it and are superseded by this Agreement.

17.3.       
The provisions of this Agreement shall be deemed separable. If any part of this Agreement is rendered void, invalid, or
unenforceable, such determination shall not affect the validity or enforceability of the remainder of this Agreement unless the
part or parts which are void, invalid or unenforceable shall substantially impair the value of the entire Agreement as to either
party.

17.4.       
Paragraph headings are inserted for convenience of reference only and do not form a part of this Agreement.

17.5.       
No person not a party to this Agreement, including any employee of any party to this Agreement, shall have or acquire any
rights by reason of this Agreement. Nothing contained in this Agreement shall be deemed to constitute the parties partners with
each other or any third party.

17.6.       
This Agreement may not be amended or modified except by written agreement executed by each of the parties. This Agreement
is personal to LICENSEE and shall not be assigned by LICENSEE without the prior written consent of YALE; except that, subject to
the conditions below, LICENSEE may assign the Agreement in the event of any CHANGE OF CONTROL without any written consent.

    	20

    	 

    

Prior to any assignment, the following
conditions must be met:

(a)               
LICENSEE must give YALE reasonable written notice, but not less than Ten (10) business days, of the assignment, including
the new assignee’s contact information; and

(b)              
The new assignee must agree in writing to YALE to be bound by the Agreement; and

(c)               
The new assignee must provided representation in writing that it has financial resources of no less than One Million Dollars
($1,000,000.00) to commit to the development and commercialization of LICENSED PRODUCTS.

17.7.       
LICENSEE, or any SUBLICENSEE or assignee, will not create, assume or permit to exist any lien, pledge, security interest
or other encumbrance on this Agreement or any sublicense.

17.8.       
The failure of any party hereto to enforce at any time, or for any period of time, any provision of this Agreement shall
not be construed as a waiver of either such provision or of the right of such party thereafter to enforce each and every provision
of this Agreement.

17.9.       
Neither Party shall be liable for delay or failure in the performance of any of its obligations hereunder if such delay
or failure is due to causes beyond its reasonable control, including, without limitation, acts of God, fires, earthquakes, strikes
and labor disputes, acts of war, terrorism, civil unrest or intervention of any governmental authority (“Force Majeure”);
provided, however, that the affected Party promptly notifies the other Party and further provided that the affected Party shall
use its reasonable best efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence,
and shall continue performance with the utmost dispatch whenever such causes are removed. When such circumstances arise, the Parties
shall negotiate in good faith any modifications of the terms of this Agreement that may be necessary or appropriate in order to
arrive at an equitable solution.

17.10.   
This Agreement may be executed in any number of counterparts and any party may execute any such counterpart, each of which
when executed and delivered shall be deemed to be an original and all of which counterparts taken together shall constitute but
one and the same instrument.

IN WITNESS to their Agreement, the parties
have caused this Agreement to be executed in duplicate originals by their duly authorized representatives.

	
        YALE UNIVERSITY

         

         
	
        HYGEIA THERAPEUTICS, INC.

         

         

	
        By:/s/                                                             

         

        E. Jonathan Soderstrom, Ph.D.

        Managing Director

        Officer of Cooperative
Research

         

        Date:                                                               
	
        By:/s/                                                             

         

        Name: Yael Schwartz, Ph.D.

         

        Title: President and CEO

         

        Date:                                                               

 

    	21

    	 

    

 

Appendix A

LICENSED PATENTS

U.S. patent number 7,015,211 issued on March 21, 2006.

    	22

    	 

    

 

 

    	23

    	 

    

FIRST AMENDMENT TO THE EXCLUSIVE
LICENSE AGItEEMENT

THIS FIRST AMENDMENT TO THE EXCLUSIVE
LICENSE AGREEMENT (this “Amendment”) is entered into as of the date of final signature below (the “Effective
Date”), by and between Yale University, a corporation organized and existing under and by virtue of a charter granted by
the general assembly of the Cefony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and Hygeia
Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware, and with principal offices located
at 8 Canterbury Lane, Holden, MA 01520 (“LICENSEE”).

RECITALS

Whereas YALE and LICENSEE are parties
to the License Agreement, effective as of October 26th, 2007 (the “Agreement”), which sets forth the terms and conditions
under which LICENSEE has rights to YALE’s invention entitled “15a-Substituted Estradiol Carboxylic Acid Esters as Locally
Active Estrogens (OCR #1400)”.

Whereas YALE and LICENSEE desire to modify
the Agreement, as set forth below,

Now therefore, in consideration of the
mutual covenants and undertakings of the parties hereto, and for other good and valuable consideration, the receipt and legal sufficiency
of which are hereby acknowledged, accepted and agreed to, the parties hereto, intending to be legally bound, do hereby agree as
follows:

1. Amendment to Section 1.1. The following
language is hereby substituted for the existing text of Section 1.1 of the Agreement:

“In the course of research conducted
under YALE auspices, Dr. Richard B. Hochberg, in the Department of Obstetrics, Gynecology and Reproductive Sciences at YALE (the
“INVENTOR”), has produced an invention entitled “15-a-Substituted Estradiol Carboxylic Acid Esters as Locally
Active Estrogens (OCR #1400)” and an invention entitled “Estradiol 16-a-Carboxylic Acid Esters as Locally Active Estrogens
(OCR #1151)”, (lointly the “INVENTION’).”

2. Amendment to Section 4.2 of the Agreement.
The following language is hereby added to the existing text of Section 4.2 of the Agreement:

“For avoidance of doubt and for
clarification purposes, it is agreed and understood that, to the extent that, any and all actions taken and completed by a SUBLICENSEE,
including, without limitation, Articles 4 and 7 and the Due Diligence obligations, that are required of the LICENSEE and that are,
in fact, performed by the SUBLICENSEE in compliance with the requirements of this Agreement, shall automatically, and without the
requirement of any further act or deed fulfill, satisfy and complete the LICENSEE’s obligations, solely with respect to such
actions completed by the SUBLICENSEE, under this Agreement.”

    	24

    	 

    

3. Amendment to Section 5.2. The following
language is hereby added to the existing text of Section 5.2. of the Agreement:

“Within thirty (30) days after
the Motive Date of the Amendment, LICENSEE agrees to pay to YALE Twenty-Two Thousand Two Hundred Forty-Six Dollars and Thirty-Seven
Cents ($22,246.37) as reimbursement in full for all past patent expenses incurred by YALE for the invention entitled “Estradiol
16-a-Carboxylic Acid Esters as Locally Active Estrogens (OCR. #1 15 1)”.”

4. With respect to Article 7 of the Agreement,
YALE hereby acknowledges and agrees that, as of the Effective Date of this Amendment, Sections 7.1 and 7.2 have been satisfied
by the LICENSEE in their entirety.

5. Amendment to Section 7.6(c) of the
Agreement The following language is hereby subject to the existing text of Section 7.6(c) of the Agreement:

“LICENSEE has failed to initiate
proof of concept studies in an established pre-clinical model (e.g., a primate model) within two (2) years of the Effective Date
of this Amendment.”

6. Amendment to Section 7.6(d) of the
Agreement. The following language is hereby substituted for the existing text of Section 7.6(d) of the Agreement:

“LICENSEE has failed to have raised
equity capital of no less than $1,000,000.00 within one (I) year of the Effective Date of this Amendment”

7. Amendment to Section 7.6(e) of the
Agreement. The following language is hereby substituted for the existing text of Section 7.6(e) of the Agreement:

“LICENSEE has failed to file an
IND for a LICENSED PRODUCT or LICENSED METHOD within four (4) years of the Effective Date of this Amendment.

8. Pursuant to the terms of Article 17.6
of the Agreement, YALE hereby consents to the proposed Series A Preferred Stock Financing and agrees that, as of the close of the
Series A Preferred Stock Financing, the LICENSEE will be in compliance with the provisions of Article 17.6 of the Agreement.

9. As of the Effective Date, to YALE’s
knowledge, LICENSEE is not in breach of any terms of the Agreement, as currently amended.

10. Amendment Co Appendix A. The following
language is hereby added to the existing test of Appendix A of the Agreement:

“U.S. patent number 6,476,012 issued
on November 5, 2002.”

11. Amendment to Appendix B. The revised
Appendix B attached to this Amendment is hereby accepted by YALE and substituted for the Appendix B of the Agreement.

The Next Page is the Signature Page.

    	25

    	 

    

IN WITNESS WHEREOF, the parties hereto
have caused their duly authorized officers to execute this Amendment as of the Effective Date. This Amendment may be executed
in multiple counterparts, each of which shall be deemed to be an original and shall collectively constitute one agreement.

	
        YALE UNIVERSITY

         

         
	
        HYGEIA THERAPEUTICS, INC.

         

         

	
        By:/s/                                                             

        Name:    E. Jonathan Soderstrom

        Title:      Managing Director, OCR

        Hereunto Duly Authorized

         

        Date:                                                               
	
        By:/s/                                                             

        Name:    Yael Schwartz, Ph.D.

        Title:       President and CEO

        Hereunto Duly Authorized

         

        Date:                                                               

 

 

 

 

 

 

 

    	26

    	 

    

ASSIGNMENT AND ASSUMPTION AGREEMENT

THIS ASSIGNMENT AND ASSUMPTION AGREEMENT
is made effective as of September __, 2011 (the “Effective Date”) by and between Hygeia Therapeutics, Inc., a Delaware
corporation (“Hygeia”) and Canterbury Laboratories, Inc., a Delaware corporation (“Canterbury”), each with
an address of 8 Canterbury Lane, Holden, MA 01520.

WHEREAS, Hygeia and Yale University (“Yale”)
entered into that certain Exclusive License Agreement dated June 30, 2011 with respect to licensed products that are non-prescription
products under US. patent 6,476,012 issued on November 5, 2002 with respect to Estradiol 16-a-Carboxylic Acid Esters as Locally
Active Estrogens (“Licenser);

WHEREAS, with the prior written consent
of Yale, Hygcia is entitled to assign its rights and obligations under the License;

WHEREAS, Hygeia desires to assign all
of its rights and obligations under the License to Canterbury and Canterbury desires to assume such rights and obligations;

NOW THEREFORE, in consideration of the
foregoing and the mutual covenants and agreements set forth below, the parties hereby agree to the terms set forth below.

(1)Effective as of the Effective
Date, Hygeia assigns to Canterbury all of Hygeia’s rights, title, interest, and obligations under the License and Canterbury
assumes all of Hygeia’s rights, title, interest, and obligations under the License, and Canterbury will, hereafter on a timely
basis pay, perform and discharge all of the obligations associated with the License whether arising prior to, on, or after the
Effective Date.

(2)Except for the assignment described
herein, Hygeia has never assigned, pledged, hypothecated, or otherwise transferred any of its rights, title, interest, or obligations
in or under the License to any other person or entity.

EXECUTED as of the Effective Date.

	
        HYGEIA THERAPEUTICS, INC.

         
	
        CANTERBURY LABORATORIES, INC.

         

	
        By:/s/                                                             

        Yael Schwartz, Ph.D., President and CEO

        Hereunto Duly Authorized

         

        Assented and Agreed to:

        YALE UNIVERSITY

         

        By:/s/                                                             

        E Jonathan Soderstrom, Ph.D.

        Managing Director

        Officer of Cooperative Research

        Hereunto Duly Authorized
	
        By:/s/                                                             

        Yael Schwartz, Ph.D., President and CEO

        Hereunto Duly Authorized

 

    	27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]